Product status information
Chemical reagent intended exclusively for laboratory tests (Research Use Only). It is not a medicinal product, dietary supplement or food. It is not intended for use on humans or animals. Sales only to registered research units and laboratories.
Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP) – a native, unmodified form of the compound from the line Endogenous, developed in the 1980s as a synthetic analogue of the ACTH(4-7) fragment extended with the C-terminal tripeptide Pro-Gly-Pro. This is the molecule from which the entire family descends peptides on brain function tested for neurotrophin induction: the pharmacophore core responsible for the nootropic and neuroprotective profile in preclinical models remains in its initial form, with free chain ends.
However, the free N-terminus has its price. Native Semax disappears from the bloodstream within a few minutes – the half-life of the heptapeptide is counted in minutes, not hours, because the free α-amino group of methionine at the N-terminus becomes the target of aminopeptidases before the molecule has time to fully act. This is a known feature of short regulatory peptides and the reason why stabilized forms such as N-acetyl Semax 50mg.
Native Semax, however, remains the reference starting point: its pharmacological profile is described in most of the literature, and all modifications are compared to it. Semax is delivered as lyophilisate in a 50 mg vial — powder form, which the researcher reconstitutes himself with bacteriostatic water according to the parameters of the planned experiment. The vial format is a standard starting point in preclinical protocols for neuroprotective peptides – it gives full control over the concentration and volume of the working solution and remains stable for months in the freezer. Purity verified by HPLC ≥98%, identity confirmed by mass spectrometry, COA available for each batch.
Regulatory status
Semax is registered as a medicinal product in the Russian Federation — as a nootropic and neuroprotectant in the form of nasal drops, in indications including ischemic stroke, encephalopathy and optic neuropathy. It is not registered as a drug in the EU or the USA. As a research reagent, it remains in the Research Use Only category. Communicating the product as an “over-the-counter nootropic”, “peptide by heart” or “neuroprotector for biohackers” is contrary to the Research Use Only framework.